Treating the nation's obesity epidemic with promising new medications called GLP-1s may deliver impressive results and health benefits – but carries a staggering cost. Health expenditures for U.S. adults would soar by more than $1 trillion if all obese individuals initiated a treatment plan.
"These certainly are remarkable drugs with huge potential to help those who need them and who haven't had a solution before," said Ted Hong, chief marketing and engagement officer for Solera Health. "But along with the medication comes huge costs. How do we balance the two, and what's the industry supposed to do?"
Several medical professionals tackled that question in "Addressing GLP-1 Demand with Step Therapy," a recent webinar sponsored by Solera Health.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
